BioVie reported a wider net loss of $0.68/share for Q3 2026 due to increased R&D for its Long COVID program. However, the company also announced positive Phase 2b results for its Parkinson's trial and progress on its Phase 3 liver disease program, which could offset the negative earnings news.
BioVie Inc. reported a net loss of $0.68 per share for Q3 2026, primarily driven by increased R&D spending on its Long COVID Phase 2 program. This financial performance is generally negative for a pre-revenue company. However, the filing also contained significant positive clinical updates: its SUNRISE-PD Phase 2b trial for Parkinson's disease met prespecified endpoints, and the company is finalizing the Phase 3 protocol for its BIV201 liver disease program. These clinical advancements could be a strong positive catalyst, potentially overshadowing the increased loss. Traders will weigh the increased burn rate against the progress in key pipeline assets, which could lead to volatility. The long-term implications depend on the successful progression of these clinical trials.